Another coronavirus vaccine is moving towards the finishing line, as South Korean firm SK Bioscience (KRX: 302440) announced the initiation of Phase III tests for its candidate, GBP510.
Working with GlaxoSmithKline (LSE: GSK), SK is aiming to deliver a novel nanoparticle vaccine which targets the receptor binding domain of the virus.
GBP510 is being developed in combination with GSK’s pandemic adjuvant, and boasts positive interim Phase I/II results, generating strong neutralizing antibodies in trial participants.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze